Literature DB >> 2803929

Serum C1-esterase inhibitor, an essential and independent prognosticator of gastric carcinoma.

C W Janssen1, R T Lie, H Maartmann-Moe, R Matre.   

Abstract

The preoperative concentrations of IgG were lower (P less than 0.002) and the concentrations of C4 and C1-INH higher (P less than 0.01 and P less than 0.001) in 29 patients with recurrence after potentially curative resection of gastric carcinoma, than in 31 patients alive and disease-free 5 years after surgery. These differences between the two groups of patients were consistent within each of six groups of disease extent. In each of the two groups of patients, the preoperative concentrations of IgG, C4 and C1-INH had no significant variation with the extent of disease (P greater than 0.05 or greater). Of our variables, C1-INH was the most potent prognosticator and discriminated between patients with and without recurrence with 80% accuracy. Furthermore, the predictive prognostic value of C1-INH at the time of surgery was superior to the prognostic value of the extent of disease (F values 27.00 and 12.69). Apparently, the preoperative C1-INH concentration is an essential and independent prognostic parameter of gastric carcinoma. We assume that C1-INH reflects an additional prognostic feature appropriate to the tumour or the host. Our finding that the interval between surgery and death from recurrence had an inverse relation to the preoperative C1-INH concentration also supports this assumption.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2803929      PMCID: PMC2247116          DOI: 10.1038/bjc.1989.319

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  14 in total

1.  THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO-CALLED INTESTINAL-TYPE CARCINOMA. AN ATTEMPT AT A HISTO-CLINICAL CLASSIFICATION.

Authors:  P LAUREN
Journal:  Acta Pathol Microbiol Scand       Date:  1965

2.  Concentrations of serum proteins and erythrocyte sedimentation rate in patients with different histological types of gastric carcinoma.

Authors:  C W Janssen; H Maartmann-Moe; R T Lie
Journal:  Eur J Surg Oncol       Date:  1987-06       Impact factor: 4.424

3.  Lysozyme and complement factors in sera from children with acute lymphoblastic leukemia.

Authors:  M E Koller; B Haneberg; R Matre; P H Finne; I Romslo
Journal:  Acta Paediatr Scand       Date:  1979-03

4.  Stage-related correlations between immunoglobulins and complement components in preoperative sera from patients with gastric carcinoma.

Authors:  C W Janssen; O Tönder; R Matre
Journal:  Eur J Cancer Clin Oncol       Date:  1983-11

5.  Letter: C1-esterase inactivators and C4 in malignant diseases.

Authors:  N Bach-Martensen; K Osther; I Stroyer
Journal:  Lancet       Date:  1975-09-13       Impact factor: 79.321

6.  Carcinoembryonic antigen in gastric cancer patients.

Authors:  N Shimizu; T Wakatsuki; A Murakami; H Yoshioka; R Hamazoe; H Kanayama; M Maeta; S Koga
Journal:  Oncology       Date:  1987       Impact factor: 2.935

7.  Factors influencing prognosis in gastric cancer.

Authors:  L C Hartley; E Evans; C J Windsor
Journal:  Aust N Z J Surg       Date:  1987-01

8.  Gastric cancer with special reference to prognostic factors. A review of 779 cases.

Authors:  J Nielsen; J Aagaard; C Toftgaard
Journal:  Acta Chir Scand       Date:  1985

9.  The prognostic value of preoperative serum immunoglobulin and complement component concentrations in patients with gastric carcinoma.

Authors:  C W Janssen; O Tønder; R Matre
Journal:  Acta Chir Scand       Date:  1985

10.  Complement C1-inactivator in the serum of patients with malignant disease.

Authors:  J Astrup; H Colstrup; B Frandsen
Journal:  Acta Radiol Ther Phys Biol       Date:  1977-10
View more
  1 in total

1.  The influence of the host on the course of gastric carcinoma.

Authors:  C W Janssen; R T Lie; C F Bassøe; H Maartmann-Moe; R Matre
Journal:  Br J Cancer       Date:  1992-11       Impact factor: 7.640

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.